Climb Bio Inc
CLYM1.700USD
+0.250+17.24%
交易中 （美東）報價延遲15分鐘
114.88M總市值
虧損本益比TTM
關於 Climb Bio Inc 公司
Climb Bio, Inc.（前身爲 Eliem Therapeutics, Inc.）是一家臨牀階段的生物技術公司。該公司專注於爲患有免疫介導疾病的患者開發治療方法。該公司的主要候選產品 budoprutug 是一種抗 CD19 單克隆抗體，旨在消耗 CD19 陽性 B 細胞（包括抗體分泌細胞），以直接減少致病性自身抗體。自身抗體的減少有可能改善自身抗體驅動疾病，例如系統性紅斑狼瘡、免疫性血小板減少症和膜性腎病。budoprutug 正處於 I 期臨牀試驗階段。
公司簡介
公司代碼CLYM
公司名稱Climb Bio Inc
上市日期Aug 10, 2021
CEODr. Aoife M. Brennan
員工數量17
證券類型Ordinary Share
年結日Aug 10
公司地址20 William Street
城市WELLESLEY HILLS
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02481
電話18668572596
網址https://climbbio.com/
公司代碼CLYM
上市日期Aug 10, 2021
CEODr. Aoife M. Brennan
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
持股股東
持股股東
佔比
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
股東類型
持股股東
佔比
Venture Capital
54.93%
Investment Advisor
12.36%
Hedge Fund
11.49%
Corporation
7.41%
Research Firm
3.67%
Investment Advisor/Hedge Fund
2.47%
Individual Investor
0.67%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
6.93%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
168
62.90M
93.07%
-4.49M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
2023Q1
92
25.90M
96.01%
-3.10M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
31.42M
46.49%
--
--
Mar 31, 2025
Pontifax Venture Capital
5.21M
7.7%
+5.21M
--
Mar 31, 2025
Access Industries, Inc.
5.01M
7.41%
--
--
Aug 14, 2024
BlackRock Institutional Trust Company, N.A.
2.10M
3.1%
-10.56K
-0.50%
Mar 31, 2025
Cantor Fitzgerald, L.P
2.00M
2.96%
+1.35M
+207.37%
Mar 31, 2025
Citi Investment Research (US)
1.85M
2.74%
+1.83M
+8039.18%
Mar 31, 2025
The Vanguard Group, Inc.
1.50M
2.22%
-3.70K
-0.25%
Mar 31, 2025
Affinity Asset Advisors LLC
1.50M
2.22%
+1.00M
+200.00%
Mar 31, 2025
Kynam Capital Management LP
1.05M
1.55%
+500.00K
+91.41%
Mar 31, 2025
Deep Track Capital LP
1.04M
1.54%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Micro-Cap ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Neuroscience and Healthcare ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
